We are live on ! Find out more
RPSM

Royalty Pharma Sub-Manager Portfolio holdings

AUM $173M
This Fund
S&P 500
This Quarter Est. Return
+3.13%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$171M
AUM Growth
–
Cap. Flow
+$147M
Cap. Flow %
85.66%
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$61M
2
BHVN icon
Biohaven
BHVN
+$36.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$27.8M
4
BCAX
Bicara Therapeutics
BCAX
+$21.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.8B
$62.3M 36.36%
+980,392
New +$61M
BCAX
2
Bicara Therapeutics
BCAX
$1.74B
$45.9M 26.77%
+1,263,150
New +$21.6M
BHVN icon
3
Biohaven
BHVN
$2.04B
$33.2M 19.35%
+2,936,507
New +$36.4M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.45B
$30M 17.51%
+3,846,154
New +$27.8M

Similar funds

BAM
Bullseye Asset Management Denver, Colorado $173M AUM 9.48% 1-Year Est. Return
MC
Marest Capital Tarzana, California $173M AUM 17.48% 1-Year Est. Return
KIM
Kurv Investment Management San Francisco, California $173M AUM
CTEF
Capital Today Evergreen Fund Grand Cayman, Cayman Islands $173M AUM 9.07% 1-Year Est. Return
PWM
Peterson Wealth Management Sparks, Nevada $172M AUM 22.85% 1-Year Est. Return
GWCM
Godshalk Welsh Capital Management Radnor, Pennsylvania $172M AUM 16.03% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $173M AUM
TA
Tiptree Advisors New York $172M AUM 86.65% 1-Year Est. Return

Royalty Pharma Sub-Manager's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Royalty Pharma Sub-Manager, which disclosed 4 positions worth $171M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Cytokinetics: 980,392 shares worth $62.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Royalty Pharma Sub-Manager's largest Q4 2025 buy was Cytokinetics: 980,392 shares worth $62.3M.
  • Royalty Pharma Sub-Manager's ten largest holdings make up 100% of its $171M portfolio in Q4 2025.
  • Royalty Pharma Sub-Manager disclosed 4 positions in Q4 2025, its first 13F filing on record.

Based on Royalty Pharma Sub-Manager's 13F filing for Q4 2025, filed 1 Apr 2026.